Pegfilgrastim

Generic Name
Pegfilgrastim
Brand Names
Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
Drug Type
Biotech
Chemical Formula
-
CAS Number
208265-92-3
Unique Ingredient Identifier
3A58010674
Background

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...

Indication

Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non­ myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...

Associated Conditions
Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
Associated Therapies
-
Clinical Trials
Related News

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

First Posted Date
2022-09-10
Last Posted Date
2024-10-29
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
120
Registration Number
NCT05535166
Locations
🇺🇸

Primary Children's Hospital, Salt Lake City, Utah, United States

🇺🇸

Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States

🇺🇸

Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States

and more 7 locations

Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant

Phase 2
Completed
Conditions
Myeloma Multiple
Lymphoma
Interventions
Drug: Pegfilgrastim
First Posted Date
2022-04-20
Last Posted Date
2023-02-28
Lead Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Target Recruit Count
30
Registration Number
NCT05338047
Locations
🇲🇽

Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León, Mexico

Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer

Phase 3
Completed
Conditions
Neutropenia
Interventions
Drug: Pegfilgrastim
First Posted Date
2022-03-17
Last Posted Date
2024-03-19
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
122
Registration Number
NCT05283616
Locations
🇨🇳

Department of Medical Oncology, Beijing, Beijing, China

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

First Posted Date
2021-09-02
Last Posted Date
2024-10-22
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
4
Registration Number
NCT05032183
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

First Posted Date
2021-08-18
Last Posted Date
2023-09-15
Lead Sponsor
Rahul Aggarwal
Target Recruit Count
36
Registration Number
NCT05011188
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Phase 4
Active, not recruiting
Conditions
Early-stage Breast Cancer
Interventions
Drug: Filgrastim
Drug: Pegfilgrastim
First Posted Date
2021-03-04
Last Posted Date
2023-03-23
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
233
Registration Number
NCT04781959
Locations
🇨🇦

Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

🇨🇦

Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

First Posted Date
2021-02-21
Last Posted Date
2022-04-26
Lead Sponsor
Wake Forest University Health Sciences
Registration Number
NCT04762901

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

First Posted Date
2021-02-18
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
244
Registration Number
NCT04759586
Locations
🇺🇸

Valley Children's Hospital, Madera, California, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

USA Health Strada Patient Care Center, Mobile, Alabama, United States

and more 226 locations

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

First Posted Date
2020-12-24
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
160
Registration Number
NCT04684368
Locations
🇺🇸

University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

🇺🇸

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States

🇦🇺

Sydney Children's Hospital, Randwick, New South Wales, Australia

and more 151 locations

An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

First Posted Date
2020-12-10
Last Posted Date
2020-12-23
Lead Sponsor
Coherus Biosciences, Inc.
Target Recruit Count
200
Registration Number
NCT04662892
Locations
🇺🇸

Carolina Blood and Cancer Care, PA, Rock Hill, South Carolina, United States

🇺🇸

Coastal Cancer Center, Myrtle Beach, South Carolina, United States

🇺🇸

Southern Oncology Specialists, Charlotte, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy